LEXICON PHARMACEUTICALS, INC. (LXRX) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$1.50

From 52W high−43.94%

Volume1.77M

Market cap$658.53M

P/E (TTM)—

P/S (TTM)15.9x

Div yield—

Key dataOct 29, 2026

Open

$1.50

From 52W high

−43.94%

Volume

1.77M

Market cap

$658.53M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.1x

P/E (TTM)

—

RSI (14)

30.4

MomentumView details →

1D Return

−0.34%

YTD Return

+26.09%

SummaryUpdated Jun 1, 2026

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company founded in 1995 and headquartered in The Woodlands, Texas. The company went public in 2000 and focuses on discovering, developing, and commercializing small molecule pharmaceutical products primarily for cardiovascular, metabolic, and neurological conditions. Lexicon has evolved from a drug discovery company into a commercial-stage biopharmaceutical company with one approved product and multiple late-stage pipeline candidates targeting significant unmet medical needs.

Ask drillr about LEXICON PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.1x

EV/Sales

12.7x

P/S (TTM)

15.9x

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

98.85%

Net Margin

−147.38%

EBITDA Margin

−126.00%

ROE (TTM)

−35.02%

ROA (TTM)

−24.44%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

−29.03%

EPS YoY

+54.56%

FCF YoY

+22.36%

Revenue CAGR 3Y

+610.25%

EPS CAGR 3Y

+77.78%

EBITDA YoY

+46.67%

MomentumView details →

1D Return

−0.34%

YTD Return

+26.09%

1Y Return

+8.21%

RSI (14)

30.4

vs 50D SMA

−23.82%

vs 200D SMA

−23.02%

Capital & dividendView details →

Debt/Equity

0.34x

Current Ratio

13.37x

Quick Ratio

13.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.06

EPS Surprise

−19.45%

Beats (12Q)

7/12

Next Q EPS Est

−$0.04

Avg Surprise (4Q)

39.94%

Rev Surprise

−82.66%

Financials snapshotView financials →

Revenue (TTM)

41.47M

Net Income (TTM)

−61.12M

Op. CF (TTM)

−79.72M

Next earningsNov 5, 2026 →

Latest newsMore news →

LEXICON PHARMACEUTICALS, INC. highlighted findings from two newly reported preclinical studies showing favorable effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy and on platelet activity and thrombus formation.9d ago

Similar companies

SL Science Holding Limited Ordinary SharesSLBT Candel Therapeutics, Inc.CADL Adlai Nortye Ltd.ANL Immix Biopharma, Inc.IMMX Aura Biosciences, Inc.AURA DBV Technologies S.A.DBVT Find similar companies →

Latest newsMore news →

LEXICON PHARMACEUTICALS, INC. announced that it will release its third-quarter 2026 financial results before market open on November 5, 2026, and hold a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update.1d ago LEXICON PHARMACEUTICALS, INC. highlighted findings from two newly reported preclinical studies showing favorable effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy and on platelet activity and thrombus formation.9d ago